Drug
Piperacillin + Tazobactam
Piperacillin + Tazobactam is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
25%
Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
completed250%
not_yet_recruiting125%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
NCT07556107
completedphase_3
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
NCT02473263
unknownphase_2
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
NCT05060419
completednot_applicable
Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors
NCT03765645
Clinical Trials (4)
Showing 4 of 4 trials
NCT07556107Phase 4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
NCT02473263Phase 3
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
NCT05060419Phase 2
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
NCT03765645Not Applicable
Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4